top of page

Samso Insights

Long-form analysis of commodities, markets and themes.

Recce Pharmaceuticals (ASX: RCE) - The Science Behind R327 and the Phase 3 Review Ahead

 LATEST INSIGHT 

Recce Pharmaceuticals' synthetic antibiotic R327, what its Phase 3 trials have and have not shown, the Arrotex licence, and the cash, debt and AGM.

5 NOV 2026 · 37 MIN READ

Data Centres in Australia - Where to Build One and Why

SAMSO INSIGHTS

Data centres in Australia, and where a new one could go. Sydney, Melbourne, Brisbane and Perth compared on power, the grid queue, prices and planning.

4 NOV 2026 · 28 MIN READ

Island Pharmaceuticals (ASX: ILA) - Galidesivir, Marburg and the Ebola Outbreak

SAMSO INSIGHTS

Island Pharmaceuticals (ASX ILA) is taking galidesivir to the FDA for Marburg. We cover the monkey data, the Ebola outbreak, the timeline and the...

4 NOV 2026 · 34 MIN READ

"The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints." - Read full disclaimer.

Be a Samso Member

Join free and get new Samso Insights in your inbox as they are published. You can leave any time. If Samso's independent research is useful to you, you can also support our work.

What do you get as a Samso Member?

  • New Samso Insights in your inbox, free. Long-form analysis of commodities, markets and themes.
  • Research notes on ASX companies. Every note declares whether it was commissioned.
  • Conversations with the people running ASX companies, through Coffee with Samso.
  • No price targets, no valuations and no buy, sell or hold calls.
  • You can leave any time.

 

Sign up as a Member now

​

bottom of page